⌕
Krystal Biotech · KRYS · Nasdaq
Tenet 66 · Solid
Compare
$298.55+0.22%At closeTenet 66 · Solid
$298.55+0.65 (+0.22%)
At close: Nov 17, 2026, 4:00 PM ET· Nasdaq · USD

Krystal Biotech (KRYS) Stock

Krystal Biotech (KRYS) closed at $298.55 on Nov 17, 2026; its Tenet Score is 66 of 100 against 340 Healthcare peers.

Sources Company filings, market prices and computed by Tenet Filings, prices and TenetScore as of How we compute thisNot investment advice

5 figures withheld by our checks. Each blank figure names its reason.

Key stats

Close
$298.55
Nov 17, 2026
Market cap
$8.8B
share price × the latest quarter's diluted weighted-average share count (vendor)
P/E
40.8×
TTM through Sep 30, 2026 · as of close, Nov 16, 2026
52-week range
198.02 – 382.54
low → high · as of close, Nov 16, 2026
Tenet Score
66/100
Solid · 340 Healthcare peers

Industry: Drugs

Krystal Biotech Inc scores 66/100. Solid. Strongest on financial health and quality, value is the soft spot, trading at 41× earnings versus 340 Healthcare peers. Insufficient inputs: Tenet 66 is built from 3 of 4 pillars, from 85% of its inputs. Growth is left out because no growth rate could be measured.

Tenet Score · vs sector

n=340
66/ 100
Solid
Fundamental composite — rates the business, not the timing.
Each metric's standing vs the company's own record is shown on the Statistics tab.
Value
32
Quality
81
Health
84
Growth
—

Factor grades

Grid rings: 25 · 50 · 75 · 100 percentile
Growth omitted — no data yet.
ValueDQualityBHealthBGrowth—MomentumB
A grade is a label over the shown score. Value/Quality/Health/Growth are sector percentiles; Momentum ranks 12−1 return across the equity universe — a lens, never folded into the Tenet Score.
Show the math →

Price

Loading chart…
P/B
6.1×
Sep 30, 2026 balance sheet
P/S
18.8×
price to sales, TTM through Sep 30, 2026 · as of close, Nov 16, 2026
ROE
17%
TTM through Sep 30, 2026
Operating margin
41.5%
fiscal 2025, before interest and tax
Net margin
47.9%
TTM through Sep 30, 2026
Current ratio
7.89
Sep 30, 2026 balance sheet
Net debt / EBITDA
−3.9×
TTM through Sep 30, 2026
EPS CAGR 5y
—
This growth figure starts in a period outside the history your plan includes.
Div yield
—
no yield on file

The whole report, at a glance · every card is a live peek, click any to open the section

About Krystal Biotech Inc

Krystal Biotech, Inc., a clinical stage biotechnology company, engages in the field of redosable gene therapy to treat serious rare diseases in the United States. Its lead product candidate is beremagene geperpavec (B-VEC), which is in Phase III clinical st…

Composite computed Nov 16, 2026 · peer basis: Healthcare (n=340) · every glimpse links to its full section with sources · not investment advice.

ETF exposure

held by 152 US ETFs · top wrappers by weightSee all ETFs holding KRYS →

Similar-sized companies in Drugs

The 10 companies in this industry closest in market cap, as of Nov 16, 2026.

What sector and industry is Krystal Biotech in?

Krystal Biotech is in the Healthcare sector and the Drugs industry.

What is Krystal Biotech's Tenet Score?

Krystal Biotech's Tenet Score is 66 out of 100, ranked against 340 Healthcare peers as of Nov 16, 2026.

Install Tenet on your phone

Tenet home pageMethodology© 2026 Tenet Investing Inc.

Data from Intrinio and Financial Modeling Prep.